combination trial with agmen, page-24

'Just seems aimless' - only thing aimless is looking for the next big thing when its already here IMO. Im staying put and accumulating , enterprise value somewhere around the $18m mark with cash around $11m - large R&D going forward so some refund of that from the Gov expected back.

A successful cancer diagnostic using PAT-SM6 would be worth more than current market value imo , making someone's cancer stable after all has failed as already proven is worth multiples of that value i think, and those with higher doses are stable longer or therapy free as reported a potentially major indicator of success going forward.

BNO was punished recently because its combination cancer results were not what the market was expecting yet the company is still highly valued around $230m .

The directors and major shareholders of PAB supported the recent 5c cap raise unlike some other BIO'S where directors are mainly sitting on options.

Final Data Confirms Successful Phase I/IIa
Clinical Trial for PAT-SM6

33% of patients showed evidence of stable disease; 2 patients for more than 130 days , A clinically-relevant mean time to next therapy of 51 days , PAT-SM6 specifically targets myeloma tumour cells in vivo and stimulates signifcant immune responses , All dose levels administered were safe with no adverse events observed , No evidence of immunogenicity; PK analysis showed PAT-SM6 to have a half-life of 7 hrs